adobe stock - JHVEPhoto Boehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.
ADVERTISEMENT
Boehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.